Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

RNA

Atrium Therapeutics Inc

13.51

Aug 19 • 3:06 PM ET +0.67 (5.21%)

Healthcare Biotechnology USA Micro NASD

Peers: OABI CAMP HUMA TNXP UNCY WHWK MIST CNTX TENX KPTI

| Held by: VTI IWM VXF IWO SCHA VTWO IWC IWN MOON FESM

Scroll to Statements

Index	-
Market Cap	231.09M
Enterprise Value	-31.44M
Income	-
Sales	-
Book/sh	12.54
Cash/sh	15.45
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Jun 12, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.08
P/C	0.87
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	8.73
Current Ratio	8.73
Debt/Eq	0.01
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-7.10
EPS next Q	-0.87
EPS this Y	-2.12%
EPS next Y	-55.14%
EPS next 5Y	-13.39%
EPS past 3/5Y	-178.43% -
Sales past 3/5Y	38.09% -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-170.95%
Sales Q/Q	90.97%
Earnings	Aug 13 AMC
EPS/Sales Surpr.	16.75% 350.58%

Insider Own	0.22%
Insider Trans	0.00%
Inst Own	83.11%
Inst Trans	235.74%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	12.27%
SMA50	8.90%
SMA200	3.73%
Trades

Shs Outstand	17.11M
Shs Float	17.09M
Short Float	20.56%
Short Ratio	18.27
Short Interest	3.51M
52W High	16.77 -19.44%
52W Low	11.13 21.38%
Volatility	3.93% 3.36%
ATR (14)	0.45
RSI (14)	68.88
Beta	-
Rel Volume	1.24
Avg Volume	192.31K
Volume	206,473

Perf Week	11.01%
Perf Month	9.92%
Perf Quarter	4.32%
Perf Half Y	-
Perf YTD	-7.34%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	25.00
Prev Close	12.84
Price	13.51
Change %	5.21%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-06-26	Initiated	H.C. Wainwright	Buy	$25
Jun-18-26	Initiated	Cantor Fitzgerald	Overweight	$25
May-15-26	Initiated	Leerink Partners	Outperform	$25
Mar-11-26	Initiated	Wells Fargo	Overweight	$25
Sep-17-25	Initiated	Roth Capital	Buy	$62
Jul-10-25	Resumed	Goldman	Buy	$55
Jun-24-25	Initiated	Bernstein	Outperform	$50
Jun-17-25	Initiated	Wolfe Research	Outperform	$55
Jun-11-25	Initiated	Raymond James	Strong Buy	$65
Mar-13-25	Initiated	Citigroup	Buy	$70
Mar-12-25	Initiated	BMO Capital Markets	Outperform	$72
Mar-07-25	Initiated	Scotiabank	Sector Outperform	$70
Dec-20-24	Initiated	H.C. Wainwright	Buy	$72
Nov-26-24	Initiated	RBC Capital Mkts	Outperform	$67
Sep-24-24	Initiated	Goldman	Buy	$59
Aug-28-24	Initiated	Barclays	Overweight	$63
May-03-24	Initiated	BofA Securities	Buy	$40
Mar-14-24	Initiated	Cantor Fitzgerald	Overweight	$60
May-22-23	Upgrade	Evercore ISI	In-line → Outperform	$20
Mar-31-23	Downgrade	Evercore ISI	Outperform → In-line	$20

Show Previous Ratings

Aug-13-26 04:44PM	Atrium Therapeutics Reports Second Quarter 2026 Financial Results (PR Newswire)
08:00AM	Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration (PR Newswire)
Aug-06-26 09:48AM	Zillow downgraded, Global Payments upgraded: Wall Street's top analyst calls (The Fly)
Jul-20-26 05:58PM	Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jun-23-26 04:05PM	Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
04:40PM	Loading…
May-14-26 04:40PM	Atrium Therapeutics Reports First Quarter 2026 Financial Results (PR Newswire)
Apr-23-26 08:00AM	Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration (PR Newswire)
Apr-20-26 10:46PM	Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -5.38%
Mar-19-26 04:00AM	Novartis acquisition spin-off pioneers RNA therapeutics for the heart (Pharma Voice)
Mar-17-26 08:09AM	Novartis Raises $11 Billion Bond to Fund $12 Billion Avidity Deal (GuruFocus.com)
Feb-27-26 04:05PM	Avidity (RNA) Moves Date for Shareholder Vote on Novartis Merger (Insider Monkey)
09:19AM	Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies (PR Newswire)
07:58AM	Atrium spins out of Avidity, aiming to target rare heart diseases with RNA (BioPharma Dive)
Feb-26-26 04:02PM	Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (PR Newswire)
Feb-23-26 08:00AM	Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders (PR Newswire)
05:00PM	Loading…
Feb-18-26 05:00PM	The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1 (PR Newswire)
Feb-04-26 09:32AM	Novartis Beats on Q4 Earnings, Entresto Generics Pressure Sales (Zacks)
Feb-02-26 09:44PM	Avidity Biosciences Announces Expected Record Date for Spin-Off (PR Newswire)
Jan-22-26 07:10AM	Immunocore (IMCR) Soars 5.9%: Is Further Upside Left in the Stock? (Zacks)
Jan-13-26 11:43AM	JPM26: Novartis strengthens neuroscience portfolio with bolt-on deals (Pharmaceutical Technology)
Dec-09-25 08:57AM	Novartis Drops $1.7 Billion on AI Allergy Breakthrough (GuruFocus.com)
Dec-04-25 01:59PM	Avidity Biosciences, Inc. (RNA): A Bull Case Theory (Insider Monkey)
Dec-01-25 06:59PM	Halper Sadeh LLC Encourages RNA, TCBX, ATXS, FSUN Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
Nov-25-25 02:00PM	FDA Greenlights Novartis' Gene Replacement Treatment for SMA (Zacks)
01:08PM	Sarepta's Stock Rises on Positive Updates on DM1 Therapy (Zacks)
Nov-21-25 10:15AM	NVS Ups Sales Projections as Key Drugs and Collaborations Fuel Growth (Zacks)
Nov-20-25 03:45PM	These 15 stocks are still showing momentum - and a market-beating edge (MarketWatch)
09:31AM	US healthcare group Abbott bets on cancer screening technology in $23bn deal (Financial Times)
01:51AM	Novartis Expects Steady Sales Growth Through 2030 (The Wall Street Journal)
Nov-10-25 05:25PM	Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
04:05PM	Loading…
04:05PM	Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights (PR Newswire)
Nov-07-25 04:34PM	Halper Sadeh LLC Encourages WTRG, PLYM, RNA Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
Nov-04-25 10:00AM	Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Nov-03-25 01:34AM	Avidity Biosciences (RNA) Soars 42% on $12-Billion Novartis Merger (Insider Monkey)
Oct-31-25 09:44AM	Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think) (Motley Fool)
Oct-30-25 12:23PM	Halper Sadeh LLC Encourages RNA, JAMF, AWK Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
10:00AM	Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-29-25 02:49PM	Fresh List of Stocks With Short Squeeze Potential (Schaeffer's Research)
Oct-28-25 10:14AM	Novartis Lags Q3 Earnings, Announces $12B Avidity Biosciences Acquisition (Zacks)
09:42AM	Warner Bros. Discovery upgraded, F5 downgraded: Wall Street's top analyst calls (The Fly)
09:17AM	Avidity Biosciences (RNA) Moves 42.4% Higher: Will This Strength Last? (Zacks)
06:26AM	Novartis Expects to Ride Out Patent Losses With Sales, Profit Growth Ahead (The Wall Street Journal)
06:11AM	S&P Futures Muted After Record Rally, FOMC Meeting and Earnings in Focus (Barchart)
05:24AM	Avidity Biosciences (RNA) Soars to All-Time High on Looming $12-Billion Merger with Novartis (Insider Monkey)
04:00AM	Novartis $12B Avidity deal shows a willingness to take big swings in neuroscience (Pharma Voice)
Oct-27-25 05:12PM	Why Avidity Biosciences Stock Blasted 42% Higher Today (Motley Fool)
05:09PM	Health Care Roundup: Market Talk (The Wall Street Journal)
04:54PM	This biotech's stock soared as investors look for the next buyout target (MarketWatch)
04:51PM	Stocks to Watch Monday: Amazon, Nvidia, Novartis, Keurig Dr Pepper (The Wall Street Journal)
04:34PM	These Stocks Are Moving the Most Today: Qualcomm, MP Materials, USA Rare Earth, Tesla, Avidity, Newmont, Microsoft, and More (Barrons.com)
01:01PM	HALPER SADEH LLC ENCOURAGES ADVM, PLYM, RNA SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS (PR Newswire)
12:55PM	Novartis Just Dropped $12 Billion on a Biotech Moonshot--Here's What Investors Need to Know (GuruFocus.com)
12:07PM	Why Avidity Biosciences And Dyne Therapeutics Stocks Soared 40% Monday (Investopedia)
11:16AM	Novartis Avidity Deal Is a Green Light for Biotech Rally (Barrons.com)
09:38AM	Stocks to Watch Monday: Nvidia, Novartis, Keurig Dr Pepper (The Wall Street Journal)
09:24AM	Novartis to buy Avidity for $12B, Keurig Dr Pepper raises outlook (Yahoo Finance Video)
08:25AM	5 Things to Know Before the Stock Market Opens (Investopedia)
08:19AM	USA Rare Earth, Iren, Novartis, Softbank: Trending Stocks (Yahoo Finance Video)
06:49AM	Fed, Tech Earnings and Trump-Xi Talks. Why One Matters Most for Markets. (Barrons.com)
06:08AM	MP Materials slumps, Avidity Biosciences surges and other movers (MarketWatch)
05:51AM	Novartis agrees to buy Avidity Biosciences for $12bn (Pharmaceutical Technology)
05:26AM	Dyne, Avidity stocks soar as Novartis strikes $12 bln biotech deal (Investing.com)
04:59AM	Stock Market Today: Dow set for 200-point rise, S&P 500 and Nasdaq to pop after weekend talks between U.S. and China (MarketWatch)
04:39AM	Jefferies sees Dyne as key beneficiary of Novartis Avidity buyout (Investing.com)
04:39AM	Novartis Deal Values Avidity Biosciences At $12 Billion (Barrons.com)
Oct-26-25 05:33PM	Novartis Agrees to Acquire Avidity Biosciences for $12 Billion (The Wall Street Journal)
04:25PM	Novartis acquiring US firm Avidity Biosciences for $12 bn (AFP)
03:43PM	Swiss drugmaker Novartis to buy Avidity Biosciences for $12 billion (USA TODAY)
03:29PM	Novartis Deal Values Avidity Biosciences At $12 Billion (Barrons.com)
01:07PM	Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG (PR Newswire)
11:07AM	Novartis to acquire Avidity in $12B bet on RNA drugs for neuromuscular disease (BioPharma Dive)
Oct-16-25 09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conference (PR Newswire)
Oct-13-25 09:00AM	Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026 (PR Newswire)
07:31AM	What Makes Avidity Biosciences (RNA) an Investment Choice? (Insider Monkey)
Oct-06-25 09:00AM	Avidity Biosciences to Present Data from EXPLORE44 Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle Society (PR Newswire)
Sep-24-25 04:06AM	Avidity Biosciences (RNA) Announces Positive One-Year Data For its, Del-Zota (Insider Monkey)
Sep-17-25 09:33AM	Netflix upgraded, Five Below initiated: Wall Street's top analyst calls (The Fly)
Sep-15-25 04:01PM	Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
Sep-13-25 12:01PM	Avidity Biosciences (RNA) Gets 9% Boost from Higher PT, Rating (Insider Monkey)
Sep-12-25 06:45AM	Takeda poaches top Lilly exec; Maze soars on early PKU drug data (BioPharma Dive)
Sep-10-25 04:01PM	Avidity Biosciences Announces Proposed Public Offering of Common Stock (PR Newswire)
07:00AM	Avidity Biosciences' Del-zota Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in EXPLORE44 and EXPLORE44-OLE Phase 1/2 Trial in People Living with DMD44 (PR Newswire)
12:59AM	Cantor Fitzgerald Reiterates a Buy Rating on Avidity Biosciences (RNA) (Insider Monkey)
Aug-27-25 09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conferences (PR Newswire)
Aug-25-25 02:23PM	RNA Stock Moves More Than 30% in a Week: What's Driving This Rally? (Zacks)
Aug-14-25 09:15AM	Clene Inc. (CLNN) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Aug-13-25 08:15AM	Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Aug-12-25 05:15PM	Fate Therapeutics (FATE) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Aug-07-25 05:10PM	Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights (PR Newswire)
10:19AM	Avidity (RNA) Gets 26% Jump on Potential Takeover (Insider Monkey)
Aug-06-25 05:10PM	Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
12:47PM	Avidity Biosciences Rockets As Novartis Reportedly Mulls A Takeover Deal (Investor's Business Daily)
12:00PM	Avidity Biosciences stock soars on Novartis takeover approach report (Investing.com)
11:41AM	Novartis weighs deal for biotech Avidity Biosciences, FT reports (Reuters)
Jul-28-25 09:39AM	Facioscapulohumeral Muscular Dystrophy Pipeline Market Insight Report 2025 \| In-depth Analysis of 10+ Companies and 12+ Pipeline Drugs (GlobeNewswire)
09:00AM	Avidity Biosciences Announces Completion of Enrollment for HARBOR, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory Submission (PR Newswire)
Jul-26-25 11:03AM	Avidity (RNA) Jumps 9.2% on Drug Candidate's Breakthrough Therapy Designation (Insider Monkey)
Jul-23-25 09:00AM	Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping (PR Newswire)
Jul-13-25 06:15AM	Raymond James Predicts Up to ~760% Surge for These 2 Strong Buy Stocks (TipRanks)

Atrium Therapeutics, Inc. operates as a biopharmaceutical company that provides RNA therapeutics services to the heart to transform the standard of care for people living with cardiomyopathies. Its products pipeline includes two lead development candidates: ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy, both conditions are severe, life-threatening, rare autosomal dominant progressive cardiomyopathies with no approved treatment options and high unmet need. The company was founded on September 30, 2025 and is headquartered in San Diego, CA.

PresidentMs. Kathleen P. Gallagher

Chief Financial OfficerMr. Brendan Winslow

Pharm.D.Dr. Husam Younis Ph.D.

Chief Corporate Affairs OfficerMs. Stephanie Kenney

M.D.Dr. Steven George Hughes M.B.A.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hughes Steven George	Chief Medical Officer	Jan 21 '26	Sale	72.45	4,895	354,643	31,599	Jan 23 05:34 PM
Boyce Sarah	President and CEO	Jan 21 '26	Sale	72.45	14,387	1,042,338	269,007	Jan 23 05:34 PM
Flanagan W. Michael	Chief Scientific Officer	Jan 21 '26	Sale	72.45	6,534	473,388	85,093	Jan 23 05:33 PM
MacLean Michael F	Chief Financial Officer	Jan 21 '26	Sale	72.45	4,542	329,068	59,290	Jan 23 05:33 PM
LEVIN ARTHUR A	Director	Jan 21 '26	Sale	72.45	1,758	127,367	16,562	Jan 23 05:33 PM
McCarthy Teresa	Chief Human Resources Officer	Jan 21 '26	Sale	72.45	2,929	212,206	113,938	Jan 23 05:33 PM
Boyce Sarah	President and CEO	Jan 07 '26	Sale	72.23	8,576	619,444	283,394	Jan 09 05:13 PM
Calderaro Charles III	Chief Technical Officer	Jan 07 '26	Sale	72.23	3,727	269,201	49,797	Jan 09 05:13 PM
McCarthy Teresa	Chief Human Resources Officer	Jan 07 '26	Sale	72.23	1,965	141,932	116,867	Jan 09 05:13 PM
Moriarty John B	Chief Legal Officer	Jan 07 '26	Sale	72.23	2,374	171,474	74,557	Jan 09 05:12 PM
MacLean Michael F	Chief Financial Officer	Jan 07 '26	Sale	72.23	1,974	142,582	63,832	Jan 09 05:12 PM
Hughes Steven George	Chief Medical Officer	Jan 07 '26	Sale	72.23	2,373	171,402	36,494	Jan 09 05:12 PM
Flanagan W. Michael	Chief Scientific Officer	Jan 07 '26	Sale	72.23	2,373	171,402	91,627	Jan 09 05:12 PM
Hughes Steven George	Chief Medical Officer	Oct 22 '25	Option Exercise	10.16	2,209	22,443	41,076	Oct 24 04:56 PM
Hughes Steven George	Chief Medical Officer	Oct 22 '25	Sale	47.54	2,209	105,015	38,867	Oct 24 04:56 PM
McCarthy Teresa	Chief Human Resources Officer	Oct 15 '25	Option Exercise	22.34	20,000	446,800	117,130	Oct 17 04:27 PM
McCarthy Teresa	Chief Human Resources Officer	Oct 15 '25	Sale	50.15	20,000	1,003,058	97,130	Oct 17 04:27 PM
Mosbrooker Eric	Chief Commercial Officer	Oct 03 '25	Option Exercise	9.05	6,562	59,386	61,562	Oct 07 04:11 PM
Mosbrooker Eric	Chief Commercial Officer	Oct 03 '25	Sale	45.38	6,562	297,771	55,000	Oct 07 04:11 PM
Hughes Steven George	Chief Medical Officer	Sep 22 '25	Option Exercise	10.16	2,208	22,433	41,075	Sep 23 04:57 PM
Hughes Steven George	Chief Medical Officer	Sep 22 '25	Sale	40.58	2,208	89,601	38,867	Sep 23 04:57 PM
McCarthy Teresa	Chief Human Resources Officer	Sep 15 '25	Option Exercise	22.34	15,000	335,100	112,130	Sep 17 04:03 PM
McCarthy Teresa	Chief Human Resources Officer	Sep 15 '25	Sale	41.41	15,000	621,142	97,130	Sep 17 04:03 PM
Hughes Steven George	Chief Medical Officer	Sep 15 '25	Option Exercise	6.57	1,542	10,131	40,409	Sep 17 04:02 PM
Hughes Steven George	Chief Medical Officer	Sep 15 '25	Sale	45.41	1,542	70,022	38,867	Sep 17 04:02 PM
Flanagan W. Michael	Chief Scientific Officer	Sep 11 '25	Option Exercise	14.22	20,000	284,400	100,195	Sep 12 04:07 PM
Flanagan W. Michael	Chief Scientific Officer	Sep 11 '25	Sale	38.94	20,000	778,702	80,195	Sep 12 04:07 PM
WILLIAM MICHAEL FLANAGAN	Officer	Sep 11 '25	Proposed Sale	46.40	20,000	928,000		Sep 11 04:24 PM
WILSON TROY EDWARD	Director	Sep 05 '25	Option Exercise	12.48	14,500	180,960	83,925	Sep 09 05:53 PM
WILSON TROY EDWARD	Director	Sep 05 '25	Sale	50.00	29,500	1,475,000	54,425	Sep 09 05:53 PM
Boyce Sarah	President and CEO	Sep 05 '25	Option Exercise	1.24	50,000	62,000	355,871	Sep 05 06:56 PM
Boyce Sarah	President and CEO	Sep 05 '25	Sale	49.95	50,000	2,497,435	305,871	Sep 05 06:56 PM
Mosbrooker Eric	Chief Commercial Officer	Sep 03 '25	Option Exercise	9.05	6,563	59,395	61,563	Sep 05 06:32 PM
Mosbrooker Eric	Chief Commercial Officer	Sep 03 '25	Sale	47.07	6,563	308,936	55,000	Sep 05 06:32 PM
SARAH BOYCE	Director	Sep 05 '25	Proposed Sale	48.47	50,000	2,423,500		Sep 05 04:25 PM
WILSON TROY EDWARD	Chairman	Sep 05 '25	Proposed Sale	50.00	95,052	4,752,600		Sep 05 04:10 PM
ERIC MOSBROOKER	Officer	Sep 03 '25	Proposed Sale	47.23	19,688	929,864		Sep 03 04:31 PM
Gallagher Kathleen P.	Chief Program Officer	Sep 02 '25	Sale	47.42	188	8,915	50,204	Sep 02 08:30 PM
Boyce Sarah	President and CEO	Aug 28 '25	Option Exercise	1.24	25,000	31,000	330,871	Aug 29 04:28 PM
Boyce Sarah	President and CEO	Aug 28 '25	Sale	49.39	25,000	1,234,700	305,871	Aug 29 04:28 PM
SARAH BOYCE	Director	Aug 28 '25	Proposed Sale	47.82	25,000	1,195,500		Aug 28 04:21 PM
Hughes Steven George	Chief Medical Officer	Aug 22 '25	Option Exercise	10.16	2,208	22,433	41,075	Aug 22 05:20 PM
Hughes Steven George	Chief Medical Officer	Aug 22 '25	Sale	46.40	2,208	102,462	38,867	Aug 22 05:20 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RNA

Atrium Therapeutics Inc

Upgrade your Finviz experience